Company Name	TEIJIN REGENET CO., LTD.
Head Office	29th Floor, Kasumigaseki Common Gate West Tower, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo 100-8585, Japan TEL: +81-3-3506-4640 FAX: +81-3-3506-4127
Established	August 1, 2023
Capital	100 million yen
Shareholder (Investment ratio (%))	TEIJIN LIMITED (100%)
Employees	Employees 48 as of March 31, 2024
Board of Directors	President: Yasushi Tanaka Board of Members: Takashi Matsunaga Takashi Yamamoto, Takayuki Nakano Statutory Auditor: Masaya Noguchi
Businesses Content	Project Development Consulting and Design of Product Specification of cell & gene therapies including tissue-engineered products Contract development of manufacturing process Contract manufacturing of products for clinical research, clinical trials and commercial products

March 2021	TEIJIN LIMITED acquired ownership of Japan Tissue Engineering Co., Ltd. (J-TEC) through a public tender offer.
April 2021	TEIJIN LIMITED established Regenerative Medicine New Business Department to enhance businesses of regenerative medicines and develop associated businesses.
August 2023	TEIJIN LIMITED established TEIJIN REGENET CO.,LTD. through incorporation-type company split. TEIJIN REGENET CO.,LTD. succeeded CDMO services from TEIJIN LIMITED.
July 2024	Kashiwanoha Facility received license of manufacturing specific processed cells stipulated the Act on the Safety of Regenerative Medicine. ［Facility Number: FA3240002］
November 2024	Iwakuni Factory granted the license of manufacturing of regenerative medicine products by the Minister of Health, Labour and Welfare. ［License Number: 35FZ110001］